BETA: Please send your feedback!
Xencor
XNCR:NAS
Biotechnology
$2.06bn
SMALL cap
$36.41
(0.15%)
0.02%
since start of 2019
41.84
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Bruce Leonard Andrews Carter, PhD | Chairman | Male |
| Bassil I. Dahiyat, PhD | President, Chief Executive Officer & Director | Male |
| John J. Kuch, CPA | Secretary & Vice President-Finance | Male |
| John R. Desjarlais, PhD | Chief Scientific Officer & Senior VP-Research | Male |
| Paul A. Foster, MD | Chief Medical Officer & Senior Vice President | Male |
| Stephen L. Mayo, PhD | Founder | Male |
| Mark W. Lotz | Vice President-Regulatory Affairs | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Xencor - Competitors and Related Companies
How Xencor stacks up to its peers in the Biotechnology industry or with competing business segments.
Xencor
XNCR:NAS
Biotechnology
$2.06bn
SMALL cap
$36.41
(0.15%)
0.02%
since start of 2019
41.84
MacroGenics
MGNX:NAS
Biotechnology
$539.78mm
SMALL cap
$11.04
(-0.33%)
-0.13%
since start of 2019
-3.16
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
$22.72bn
LARGE cap
$101.31
(0.58%)
0.03%
since start of 2019
17.00
AbbVie
ABBV:NYS
Pharmaceuticals: Major
$115.57bn
MEGA cap
$78.17
(0.87%)
-0.12%
since start of 2019
28.68
Amgen
AMGN:NAS
Biotechnology
$122.49bn
MEGA cap
$204.25
(1.32%)
0.06%
since start of 2019
16.07
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
$342.93bn
MEGA cap
$129.94
(1.92%)
0.02%
since start of 2019
—